ANNUAL REPORT 2012 - TiGenix

for their healthcare and biotechnology
practice. In this function, he assisted a broad
range of companies in the biomedical
and biotech industries through different
stages of growth. Before commencing his
MBA, he worked three years as a research
engineer in environmental biotechnology.
Since June 2012, Mr. Beyen is Chairman of
the Supervisory Board at Erytech Pharma
SA, a French biopharmaceuticals company.
He also is a manager of Axxis V&C BVBA, as
well as member of the board of BIO.be, and
commissioner for the Flemish government
on the board of the Flemish Institute of
Biotechnology (VIB).
responsible for the worldwide registration
of GlaxoSmithKline’s flu franchise. With this
firm, he also served as Director of molecular
biology and research, responsible for
the development of nucleic acid and
tuberculosis vaccines, as well as immunology
research activities. Prior to joining
GlaxoSmithKline, Mr. Dalemans worked at
Transgène, France, where he was responsible
for the cystic fibrosis research program. Mr.
Dalemans currently serves as a supervisory
director of Arcarios B.V. and a director of
Arcarios NV.
7.4.3. Chief executive officer
Claudia D’Augusta : Chief Financial Officer
(CFO)
The CEO is appointed, and can be removed,
by the Board of Directors.
Ms. Claudia D’Augusta has more than
fifteen years of experience in the field of
corporate finance. After completing her
degree in Economics and a Ph.D. in Business
Administration at the University of Bocconi,
Italy, she joined the Corporate Finance
Department of Deloitte & Touche in Milan.
She later joined Apax Partners in Madrid
where she participated in the origination
and execution of M&A transactions. She was
subsequently Finance Director of Aquanima
(Santander Group). Ms. D’Augusta was a
member of the Board of Directors of Sensia
S.L. from April 2005 until April 2008.
The CEO is charged by the Board of
Directors with the day-to-day management
of the Company and is therefore also
managing director of the Company. In this
function, the CEO has the following general
responsibilities :
- examining, analysing and proposing to
the Board of Directors strategic business
opportunities that can contribute to the
further growth of the group;
- executing the decisions of the Board of
Directors;
Wilfried Dalemans : Chief Technical Officer
(CTO)
Mr. Wilfried Dalemans holds a PhD in
molecular biology from the Universities
of Hasselt and Leuven. Before joining
TiGenix, Mr. Dalemans held several senior
management positions at GlaxoSmithKline
Biologicals, Belgium. As Director regulatory
strategy and development, he was
- preparing proposals to the nomination and
remuneration committee concerning the
appointment, remuneration and evaluation
of the members of the management team;
- setting up, chairing and leading the
management team;
- managing the members of the
management team as they discharge
93